Who is sponsoring NCT03541330?

NCT03541330 is sponsored by University Hospital, Lille.

What drugs are being tested in NCT03541330?

Interventions in NCT03541330: semi-directive interview.

What condition does NCT03541330 study?

NCT03541330 studies Malignant Haemopathy.

Is NCT03541330 still recruiting?

NCT03541330 is currently terminated. Last updated 11 December 2025.

Last reviewed 2025-12-11 · How we verify

NCT03541330

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Information and Accompaniment of Siblings Following the Announcement of a Cancer in Pediatric Hematology.

Terminated NA Last updated 11 December 2025

What this trial tests

NA trial testing semi-directive interview in Malignant Haemopathy in 7 participants. Terminated before completion.

Timeline

22 October 2018

Primary endpoint
1 April 2019

1 April 2019

Quick facts

Lead sponsor	University Hospital, Lille
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	7
Start date	22 October 2018
Primary completion	1 April 2019
Estimated completion	1 April 2019
Sites	1 location across France

Drugs / interventions tested

semi-directive interview

Conditions studied

Malignant Haemopathy — all drugs for Malignant Haemopathy →

Sponsor

University Hospital, Lille

Who can join

Adults 6 to 12, any sex, with Malignant Haemopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective is to evaluate the experience with the information received on the disease by the healthy brothers and sisters of childrens with malignant haemopathy at the Centre Hospitalier Régional et Universitaire of Lille

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University Hospital, Lille trials

Trials by the same sponsor.

NCT07528664 — Assessement of a Test a Financial-incentive Program for Pregnant Women and Their Smoking Partners to Reduce Smoking Duri · NA · not yet recruiting
NCT07434739 — PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies · NA · not yet recruiting
NCT06958224 — Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers · NA · not yet recruiting
NCT07408999 — Totally Versus Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer · NA · not yet recruiting
NCT07492030 — Validation of the Use of the Arteriovenous Tension Difference in CO2 Under Hyperbaric Conditions · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03541330 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Lille
Last refreshed: 11 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03541330.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing